• KOL
    • KOLs Community
    • Lyme
    • Lyme Disease
    • Peter J Krause
    • Peter J Krause

      Peter J Krause

      Yale School of Public Health, Department of Epidemiology of Microbial Diseases and Yale School of Medicine, New Haven, Connecticut, USA. | Department of Epidemiology of ...

       

       

      KOL Resume for Peter J Krause

      Year
      2022

      Yale School of Public Health, Department of Epidemiology of Microbial Diseases and Yale School of Medicine, New Haven, Connecticut, USA.

      2021

      Yale School of Public Health and Yale School of Medicine, New Haven, CT, USA

      2020

      Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA

      Yale School of Public Health and Yale School of Medicine, New Haven Connecticut, United States

      2019

      Department of Epidemiology of Microbial Diseases, Yale School of Public Health and Departments of Medicine and Pediatrics, Yale School of Medicine, New Haven, CT, USA

      2018

      Department of Epidemiology of Microbial Diseases, Yale School of Public Health and Yale School of Medicine, New Haven, Connecticut

      Yale School of Medicine New Haven CT

      2017

      Yale School of Public Health and Yale School of Medicine, 60 College St., New Haven, CT 06520, USA

      2016

      Yale School of Public Health Division of Epidemiology of Microbial Diseases New Haven Connecticut

      2015

      Yale School of Medicine, New Haven, CT, USA

      2014

      Department of Epidemiology of Microbial Diseases Yale School of Public Health New Haven Connecticut

      2013

      Tufts University Cummings School of Veterinary Medicine North Grafton Massachusetts

      Department of Epidemiology and Public Health, Yale School of Public Health, New Haven, Connecticut.

      Yale School of Public Health and Yale School of Medicine, New Haven, Connecticut, United States of America

      Blood Systems Research Institute San Francisco California

      Emeritus, Walter Reed Army Institute of Research

      2012

      From the *Yale School of Public Health and Yale School of Medicine, New Haven, CT; and †Tufts Medical Center and Tufts University School of Medicine, Boston, MA.

      University of British Columbia, Vancouver, British Columbia, Canada (P.J. Keeling, A. Horak);

      Epidemiology and Public Health, Yale School of Medicine, New Haven, United States

      Yale School of Medicine, New Haven, Connecticut, USA (P.J. Krause, S. Bent, L. Rollend)

      2011

      Yale School of Public Health and Yale School of Medicine, New Haven, Connecticut, USA (D. Fish, P.J. Krause)

      Municipal Clinical Hospital No. 33, Yekaterinburg, Russia (N.A. Makhneva, M.G. Toporkova);

      Author affiliations: Central Research Institute of Epidemiology, Moscow, Russia (A.E. Platonov, L.S. Karan, N.M. Kolyasnikova, V.V. Maleev);

      2010

      Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, Connecticut

      2009

      Connecticut Children's Medical Center, Hartford, Connecticut.

      e‐mail: Department of Epidemiology and Public Health
Yale School of Medicine
New Haven, CT

      2008

      University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030, USA

      Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, Connecticut (Dr Krause), and the Division of Infectious Diseases, Department of Medicine, New York Medical College, Valhalla, New York (Dr Wormser).

      2007

      From the *Division of Infectious Diseases, Department of Medicine, University of Connecticut Health Center, Farmington, CT; and the †Divisions of Infectious Diseases and Cardiology, Department of Pediatrics, Connecticut Children’s Medical Center and the University of Connecticut School of Medicine, Hartford, CT.

      Department of Pediatrics, University of Connecticut School of Medicine and Connecticut Children's Medical Center, Hartford, Connecticut

      2006

      Department of Pediatrics, University of Connecticut School of Medicine and Connecticut Children's Medical Center, Hartford

      Pediatrics, University of Connecticut School of Medicine, Farmington, Connecticut 06030

      2005

      Connecticut Children's Medical Center, Hartford, Connecticut, USA;

      2003

      Department of Pediatrics, University of Connecticut School of Medicine and Connecticut Children’s Medical Center, Hartford, Connecticut

      2002

      University of Connecticut School of Medicine and the Connecticut Children's Medical Center, Hartford, CT.

      Center for Microbial Pathogenesis

      2001

      Pediatrics, and

      Division of Infectious Disease, Connecticut Children's Medical Center, Hartford, CT

      2000

      Department of Pediatrics, Connecticut Children's Medical Center, Hartford, Connecticut 06106

      University of Connecticut School of Medicine, Farmington, Connecticut

      1999

      Bacterial Zoonoses Branch, Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado; Department of Pediatrics and Department of Laboratory Medicine, University of Connecticut School of Medicine, Farmington, Connecticut; Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts; Department of Medicine, Brown University School of Medicine, Providence, Rhode Island

      The University of Connecticut, Farmington, Connecticut,2 and

      1998

      From the Department of Pediatrics, Division of Pediatric Infectious Diseases, Connecticut Children's Medical Center and University of Connecticut School of Medicine, Hartford (P.J.K., K.M., D.C., R.R.)

      1997

      Harvard School of Public Health, Boston, MA USA

      1996

      Department of Pediatrics, University of Connecticut School of Medicine, Farmington 06030, USA.

      1995

      Division of Pediatric Infectious Diseases, University of Connecticut, Farmington (P.J.K.)

       

       

      Peter J Krause: Influence Statistics

      Sample of concepts for which Peter J Krause is among the top experts in the world.
      Concept World rank
      severely immunocompromised hosts #1
      adults 31d8 mab #1
      people skin biopsies #1
      pregnancy neutrophil chemotaxis #1
      endorgan dysfunction subjects #1
      miyamotoi infection fever #1
      consists atovaquone #1
      parasitemia organ #1
      pneumonia newborn stress #1
      rce antimicrobial agents #1
      chemotaxis neonates #1
      hwa285 mortality #1
      local itch response #1
      babesiosis immunocompromised #1
      balb mice people #1
      north america babesia #1
      babesia babesia duncani #1
      toxins babesiosis #1
      pathogen standard #1
      motility leukocyte child #1
      babesiosis cytapheresis #1
      chemotaxis micropore #1
      massachusetts diagnosis #1
      suspected lifethreatening sepsis #1
      serial dilution panels #1
      human case babesia #1
      choice mildtomoderate illness #1
      borrelia miyamotoi response #1
      babesia reference strain #1
      2 ehrlichial diseases #1
      0 2086 units #1
      symptomatic powv #1
      france humans babesia #1
      0 787 units #1
      ospa antigen pathogenesis #1
      covectored pathogens approach #1
      peridomestic nymphal density #1
      malignant pertussis apheresis #1
      clindamycin quinine #1
      coma rare complications #1
      6500 unscreened units #1
      powv prevalence #1
      tickborne pathogen invasion #1
      outcomes babesiosis patients #1
      cmv antibody prevalence #1
      balb tick #1
      case babesia #1

       

      Prominent publications by Peter J Krause

      KOL-Index: 14075

      Babesia microti and Borrelia burgdorferi, the respective causative agents of human babesiosis and Lyme disease, are maintained in their enzootic cycles by the blacklegged tick (Ixodes scapularis) and use the white-footed mouse (Peromyscus leucopus) as primary reservoir host. The geographic range of both pathogens has expanded in the United States, but the spread of babesiosis has lagged behind that of Lyme disease. Several studies have estimated the basic reproduction number (R0) for B. ...

      Known for United States | Babesia Microti | Borrelia Burgdorferi | Lyme Disease | Peromyscus Leucopus
      KOL-Index: 12896

      Babesia microti, the primary cause of human babesiosis in the United States, is transmitted by Ixodes scapularis ticks; transmission may also occur through blood transfusion and transplacentally. Most infected people experience a viral-like illness that resolves without complication, but those who are immunocompromised may develop a serious and prolonged illness that is sometimes fatal. The geographic expansion and increasing incidence of human babesiosis in the northeastern and ...

      Known for Babesia Microti | Quantitative Pcr | Human Babesiosis | Ixodes Scapularis | United States
      KOL-Index: 12816

      BACKGROUND: The tick-borne pathogen Babesia microti has become recognized as the leading infectious risk associated with blood transfusion in the United States, yet no Food and Drug Administration-licensed screening tests are currently available to mitigate this risk. The aim of this study was to evaluate the performance of an investigational enzyme immunoassay (EIA) for B. microti as a screening test applied to endemic and nonendemic blood donor populations.

      STUDY DESIGN AND METHODS: ...

      Known for United States | Babesia Microti | Blood Donors | New York | Enzyme Immunoassay
      KOL-Index: 12743

      BACKGROUND: Transfusion-transmitted babesiosis caused by Babesia microti has emerged as a significant risk to the US blood supply. This study estimated the prevalence of B. microti antibodies in blood donors using an investigational enzyme immunoassay (EIA).

      STUDY DESIGN AND METHODS: A peptide-based EIA that detects both immunoglobulin (Ig)G and IgM antibodies to B. microti was developed and validated. Donor samples randomly selected from areas defined as high-risk endemic, lower-risk ...

      Known for Babesia Microti | Investigational Enzyme | Blood Donor | Pcr Eia | Transmitted Babesiosis
      KOL-Index: 12700

      Objective. —To determine whether patients coinfected with Lyme disease and babesiosis in sites where both diseases are zoonotic experience a greater number of symptoms for a longer period of time than those with either infection alone.Design. —Community-based yearly serosurvey and clinic-based cohort study.Setting. —Island community in Rhode Island and 2 Connecticut medical clinics from 1990 to 1994.Study Participants. —Long-term residents of the island community and patients seeking ...

      Known for Lyme Disease | Increased Severity | Babesiosis Patients | Duration Symptoms | Rhode Island
      KOL-Index: 12697

      We used multiparameter flow cytometry to characterize leukocyte immunophenotypes and cytokines in skin and peripheral blood of patients with erythema migrans (EM). Dermal leukocytes and cytokines were assessed in fluids aspirated from epidermal suction blisters raised over EM lesions and skin of uninfected controls. Compared with corresponding peripheral blood, EM infiltrates were enriched for T cells, monocytes/macrophages, and dendritic cells (DCs), contained lower proportions of ...

      Known for Erythema Migrans | Adaptive Immunity | Tolllike Receptor | Peripheral Blood | Cell Surface
      KOL-Index: 11980

      Borrelia miyamotoi is a relapsing fever Borrelia group spirochete that is transmitted by the same hard-bodied (ixodid) tick species that transmit the agents of Lyme disease. It was discovered in 1994 in Ixodes persulcatus ticks in Japan. B. miyamotoi species phylogenetically cluster with the relapsing fever group spirochetes, which usually are transmitted by soft-bodied (argasid) ticks or lice. B. miyamotoi infects at least six Ixodes tick species in North America and Eurasia that ...

      Known for Miyamotoi Infection | United States | Relapsing Fever | Tick Species | Lyme Disease
      KOL-Index: 11742

      To determine whether human Borrelia miyamotoi infection occurs in the far-western United States, we tested archived sera from northwestern California residents for antibodies to this emerging relapsing fever spirochete. These residents frequently were exposed to I. pacificus ticks in a region where B. miyamotoi tick infection has been reported. We used a two-step B. miyamotoi rGlpQ assay and a B. miyamotoi whole-cell lysate (WCL) assay to detect B. miyamotoi antibody. We also employed ...

      Known for Borrelia Miyamotoi | United States | Pacificus Ticks | Infections California | Relapsing Fever
      KOL-Index: 11024

      BACKGROUND: Babesiosis is an emerging tickborne malaria-like infection principally caused by Babesia microti. This infection typically resolves either spontaneously or after administration of a 7-10-day course of azithromycin plus atovaquone or clindamycin plus quinine. Although certain highly immunocompromised patients may respond suboptimally to these drug regimens, unlike the situation with malaria there has been no reported evidence that the cause of treatment failure is infection ...

      Known for Babesia Microti | Treatment Babesiosis | Immunocompromised Patients | Atovaquone Azithromycin | Drug Therapy
      KOL-Index: 10553

      BACKGROUND: Babesiosis is a tick-borne, malaria-like illness known to be enzootic in southern New England. A course of clindamycin and quinine is the standard treatment, but this regimen frequently causes adverse reactions and occasionally fails. A promising alternative treatment is atovaquone plus azithromycin.

      METHODS: We conducted a prospective, nonblinded, randomized trial of the two regimens in 58 subjects with non-life-threatening babesiosis on Nantucket, on Block Island, and in ...

      Known for Clindamycin Quinine | Atovaquone Azithromycin | Treatment Babesiosis | Protozoan Drug Therapy | Southern New England
      KOL-Index: 9780

      OBJECTIVE: A recombinant lipoprotein outer surface protein A (OspA) Lyme disease (LD) vaccine (LYMErix) has been shown to be safe and effective in preventing LD in adults and in adolescents 15 years of age and older. Children are at risk for developing LD. This clinical study was conducted to address the safety and immunogenicity of LD vaccine in children 4 to 18 years of age.

      METHODS: A randomized, placebo-controlled clinical trial was conducted at 17 investigational sites in ...

      Known for Lyme Disease | Outer Surface | Borrelia Burgdorferi | United States | Bacterial Vaccines
      KOL-Index: 9655

      Evidence-based guidelines for the management of patients with Lyme disease, human granulocytic anaplasmosis (formerly known as human granulocytic ehrlichiosis), and babesiosis were prepared by an expert panel of the Infectious Diseases Society of America. These updated guidelines replace the previous treatment guidelines published in 2000 (Clin Infect Dis 2000; 31[Suppl 1]:1-14). The guidelines are intended for use by health care providers who care for patients who either have these ...

      Known for Lyme Disease | Granulocytic Anaplasmosis | Clinical Practice Guidelines | Treatment Prevention | Antimicrobial Therapy
      KOL-Index: 9574

      OBJECTIVE: The objectives of this quality standard are 1) to provide an implementation mechanism that will facilitate the reliable administration of prophylactic antimicrobial agents to patients undergoing operative procedures in which such a practice is judged to be beneficial and 2) to provide a guideline that will help local hospital committees formulate policies and set up mechanisms for their implementation. Although standards in the medical literature spell out recommendations for ...

      Known for Surgical Procedures | Antimicrobial Prophylaxis | Prophylactic Antibiotics | Postoperative Infection | Disease Control

      Key People For Lyme Disease

      Top KOLs in the world
      #1
      Allen C Steere
      lyme disease borrelia burgdorferi united states
      #2
      Gary P Wormser
      lyme disease erythema migrans united states
      #3
      Alan G Barbour
      lyme disease borrelia burgdorferi relapsing fever
      #4
      Durland Fish
      lyme disease united states borrelia burgdorferi
      #5
      Stephen E Malawista
      lyme disease borrelia burgdorferi polymorphonuclear leukocytes
      #6
      Raymond J Dattwyler
      lyme disease borrelia burgdorferi bacterial antigens

      Peter J Krause:Expert Impact

      Concepts for whichPeter J Krausehas direct influence:Lyme disease,  Babesia microti,  Human babesiosis,  United states,  Quality standard,  New england,  Borrelia miyamotoi,  Miyamotoi infection.

      Peter J Krause:KOL impact

      Concepts related to the work of other authors for whichfor which Peter J Krause has influence:Lyme disease,  Borrelia burgdorferi,  Babesia microti,  United states,  Human babesiosis,  Antibiotic prophylaxis,  Anaplasma phagocytophilum.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      Yale School of Public Health, Department of Epidemiology of Microbial Diseases and Yale School of Medicine, New Haven, Connecticut, USA. | Department of Epidemiology of Microbial Diseases, Yale School of Public Health and Yale School of Medicine, New

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.